Q-omics provides the consensus-scored C2CD4A profile across patient tissues and cancer cell-line models. C2CD4A expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, C2CD4A is differentially expressed in 17, with the highest sampling consensus in COAD. Additionally, C2CD4A RNA expression shows 12,033 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, COAD, and TGCT as cancer lineages where C2CD4A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C2CD4A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C2CD4A survival associations across molecular data types. C2CD4A RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C2CD4A RNA expression–survival associations across cancer types. High C2CD4A expression shows unfavorable associations in KIRC, LGG, KIRP and LIHC, but favorable associations in SCLC and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for C2CD4A RNA expression.
This table summarizes C2CD4A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for C2CD4A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C2CD4A shows higher tumor expression in COAD, THCA, STAD, LUAD, HNSC and LUSC. The COAD box plot shows higher C2CD4A RNA expression in tumor versus normal tissue (log2 FC = +3.487, t-test p < 0.001).
This table shows molecular features associated with C2CD4A in patient tissues and cancer cell lines. In patient samples, C2CD4A shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, C2CD4A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LUNG_NSCLC_LUAD.
